DOW JONES NEWSWIRES

Pfizer Inc. (PFE) said late Tuesday it discontinued a Phase III clinical trial for the experimental advanced skin cancer treatment tremelimumab because early data showed it was not superior to standard chemotherapy.

Pfizer said it has notified regulators and investigators worldwide of the trial halt, and will work with researchers to see if any patients were benefitting from the drug.

Late-traded shares of Pfizer were down 2.3% to $20.90 in after-hours activity.

-Wallace Witkowski; 415-439-6400; AskNewswires@dowjones.com

  (END) Dow Jones Newswires
  04-01-08 1817ET
  Copyright (c) 2008 Dow Jones & Company, Inc.